Advertisement

Picture EBD Group BIO-Europe 2019 Partnering Report BEU2019 650x80px
Document › Details

SEngine Precision Medicine. (10/2/19). "Press Release: SEngine Precision Medicine Raises $5.1 Million Series A to Advance Personalized Oncology Drug Discovery Platform". Seattle, WA.

Organisations Organisation SEngine Precision Medicine (US)
  Organisation 2 Bangarang Group
Products Product drug discovery technology
  Product 2 venture capital
Index terms Index term SEngine Precision Medicine–SEVERAL: investment, 201910 financing round Series A $5.1m led by Bangarang Group with family offices + existing investors
  Index term 2 SEngine Precision Medicine–Atomwise: AI-based drug discovery, 201909– collab launch joint venture r+d personalised cancer drugs using gene targets
Persons Person Grandori, Carla (SEngine Precision Medicine 201909 CEO + Founder)
  Person 2 Burkland, Elliott (Bangarang Group 201910)
     


Investment to fuel SEngine’s AI integration and accelerate development of proprietary 3D tumor organoid diagnostic and drug discovery platform


SEngine Precision Medicine, an oncology pioneer accelerating cancer drug discovery through its CLIA certified, proprietary diagnostic platform PARIS®, today announced closing of a $5.1MM Series A investment round. The round has been led by the Bangarang Group with participation from various family offices and returning investors. This brings SEngine’s total funding to date to more than $9MM.

SEngine’s high-throughput screening technology simultaneously tests dozens of targeted anti-cancer agents against a patient's unique cancer cells outside the body via patient-derived 3D tumor organoids. The results decode the most effective and least toxic treatment options in just weeks, which DNA sequencing alone cannot reveal. The AI-optimized platform leverages the aggregated, anonymized test results to develop new cancer-fighting drugs. 

The PARIS® Test is currently utilized by leading oncologists throughout the United States to predict and validate personalized treatment options for their patients. SEngine Precision Medicine and Atomwise, Inc. recently announced a joint venture to accelerate novel oncology drug discovery utilizing the unique platform technologies each company has validated through years of development.

“We’re thrilled with SEngine’s technological progress which is being utilized to help cancer patients today, and we continue to see the immense potential for Dr. Grandori and her world-class team to radically transform cancer care through their personalized diagnostic platform and novel drug discovery program,” said Elliott Burkland, representing the Bangarang Group. “We’re at a fascinating moment in medicine and SEngine’s platform offers an opportunity to transform a faltering standard of care.” 

“This round of financing positions us to move quickly to both commercialize and scale our technology,” said Dr. Carla Grandori, SEngine Precision Medicine Founder and CEO. She continued, “We’re proud of the market validation and our clinical validation to continue to advance efforts we believe will revolutionize personalized and effective cancer care. We’ve assembled a stellar global team of proven biotech leaders and two of our generation’s greatest scientific minds as advisors to guide our continued success.”

Nobel Prize Laureate and past President of the Fred Hutch Cancer Center Dr. Leland Hartwell and Pulitzer Prize-winning author and oncologist Dr. Siddhartha Mukherjee both serve in senior advisory roles for SEngine. 


ABOUT SENGINE PRECISION MEDICINE:

Founded in 2015, SEngine Precision Medicine is a privately held biotech startup based in Seattle, WA and founded to identify and develop the next generation of cancer targeted drugs. Discover more at SengineMedicine.com and follow the latest news from SEngine on Twitter at @SEngineMedicine and on LinkedIn.

   
Record changed: 2019-10-01

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for SEngine Precision Medicine (US)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BIO-Europe 2019 Hamburg Germany BEU2019 iito 650x80px




» top